News Daily News For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis Yael L. Maxwell August 14, 2025
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for July 2025 Caitlin E. Cox July 31, 2025
News Conference News SCCT 2025 Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR Yael L. Maxwell July 28, 2025
News Daily News AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review Todd Neale July 24, 2025
News Conference News SCCT 2025 AI-QCT Possibly Lessens Gap Between Ideal vs Actual Care for Patients at Risk of ASCVD Yael L. Maxwell July 22, 2025
News Conference News SCCT 2025 AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry Yael L. Maxwell July 21, 2025
News Daily News Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050 Todd Neale July 16, 2025
News Daily News No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits Michael O'Riordan July 14, 2025
News Daily News FDA Approves Triple Therapy Polypill for High Blood Pressure Michael O'Riordan June 10, 2025
News Daily News Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years Yael L. Maxwell June 09, 2025
News Conference News EuroPCR 2025 ‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI Michael O'Riordan May 29, 2025
News Daily News AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease Caitlin E. Cox May 06, 2025
News Daily News High-Sensitivity Troponin Tests Might Aid in Primary Prevention Yael L. Maxwell April 16, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Daily News ACC Releases ‘Concise Clinical Guidance’ for Cardiogenic Shock Care Caitlin E. Cox March 19, 2025
News Daily News Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD Michael O'Riordan March 06, 2025
News Daily News ‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials Michael O'Riordan February 20, 2025
News Daily News Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab Michael O'Riordan February 05, 2025